Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M04 ANTIGOUT PREPARATIONS
M04A ANTIGOUT PREPARATIONS
M04AA Preparations inhibiting uric acid production
M04AA03 Febuxostat
D01206 Febuxostat (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antigout Agents
Febuxostat
D01206 Febuxostat (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
394 Gout preparations
3949 Others
D01206 Febuxostat (JAN/USAN/INN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01503 Xanthine dehydrogenase inhibitor
DG02878 Febuxostat
D01206 Febuxostat
Musculo-skeletal system agent
DG03130 Xanthin oxidase inhibitor
DG02878 Febuxostat
D01206 Febuxostat
Target-based classification of drugs [BR:br08310]
Enzymes
Oxidoreductases (EC1)
Xanthine dehydrogenase/oxidase
XDH
D01206 Febuxostat (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D01206
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D01206
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D01206
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D01206
Drug groups [BR:br08330]
Cardiovascular agent
DG01503 Xanthine dehydrogenase inhibitor
DG02878 Febuxostat
Musculo-skeletal system agent
DG03130 Xanthin oxidase inhibitor
DG02878 Febuxostat